# Avalo Therapeutics to Participate in the BTIG Biotechnology Conference
Canonical URL: https://biopharmsignal.com/news/AVTX/avalo-therapeutics-to-participate-in-the-btig-biotechnology-conference-399b4284
Ticker: AVTX
Company: Avalo Therapeutics
Source: Avalo Therapeutics
Published: 2026-07-22 11:00 EST
Original Source URL: https://ir.avalotx.com/news-events-presentations/press-releases/detail/229/avalo-therapeutics-to-participate-in-the-btig-biotechnology-conference
## Summary

WAYNE, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated…...

## Article Body
July 22, 2026 7:00am EDT

WAYNE, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, today announced that Dr. Garry Neil, Chief Executive Officer of Avalo, will participate in the “Honing in on Hidradenitis” panel at the virtual BTIG Biotechnology Conference on Wednesday, July 29, 2026, at 10:30 am ET. Management will also host one-on-one investor meetings during the conference.

Live webcasts and replays, when available, can be found under "News / Events" in the Investors section of the Avalo Therapeutics website at https://ir.avalotx.com. The archived webcast will be available for replay for at least 30 days.

About Avalo Therapeutics

Avalo Therapeutics is a clinical stage biotechnology company fully dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases. Our lead asset, abdakibart, is an anti-IL-1β monoclonal antibody (mAb). Positive topline data was recently reported for abdakibart in a Phase 2 clinical trial in hidradenitis suppurativa (HS). In addition to HS, we’re exploring additional opportunities to make an impact in prevalent indications that have significant remaining unmet needs. We are also advancing AVTX-010, a long-acting next-generation anti-IL-1β mAb designed to extend dosing intervals and build upon the differentiated profile established by abdakibart. For more information about Avalo, please visit www.avalotx.com .

For media and investor inquiries

Christopher Sullivan, CFO Avalo Therapeutics, Inc. ir@avalotx.com 410-803-6793

or

Meru Advisors Lauren Glaser lglaser@meruadvisors.com

Source: Avalo Therapeutics Released July 22, 2026
## Recent Company News
- 2026-07-22 11:00 EST — [Avalo Therapeutics to Participate in the BTIG Biotechnology Conference](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-to-participate-in-the-btig-biotechnology-conference-399b4284) — Source: Avalo Therapeutics
- 2026-07-07 11:00 EST — [Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-to-participate-in-the-leerink-partners-therapeutics-forum-ef62dbcf) — Source: Avalo Therapeutics
- 2026-06-26 11:00 EST — [Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-to-join-the-russell-2000-and-russell-3000-indexes-3ee6d18b) — Source: Avalo Therapeutics
- 2026-06-23 11:00 EST — [Avalo Therapeutics Appoints Ron Philip to Board of Directors](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-appoints-ron-philip-to-board-of-directors-7373732c) — Source: Avalo Therapeutics
- 2026-06-16 11:00 EST — [Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody](https://biopharmsignal.com/news/AVTX/avalo-therapeutics-expands-pipeline-with-avtx-010-a-long-acting-next-generation--527ab39d) — Source: Avalo Therapeutics
## Related News
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)
- 2026-07-22 12:30 EST — NRSN — [NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS](https://biopharmsignal.com/news/NRSN/neurosense-advances-primec-toward-new-drug-submission-to-health-canada-for-als-721c198c)
- 2026-07-22 12:30 EST — PRGO — [Perrigo to Release Second Quarter 2026 Financial Results on August 5, 2026](https://biopharmsignal.com/news/PRGO/perrigo-to-release-second-quarter-2026-financial-results-on-august-5-2026-ff2ea2a5)
- 2026-07-22 12:08 EST — BIAF — [bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD](https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-and-pictor-inc-partner-to-develop-and-commercialize-bio-7ee819d4)
- 2026-07-22 12:00 EST — MNPR — [Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease](https://biopharmsignal.com/news/MNPR/monopar-initiates-rolling-nda-submission-for-alxn1840-in-wilson-disease-e671ddcf)